Publications and projects according to DDC
Publications
Publications and projects according to DDC 615: Pharmacology and therapeutics
-
Scheermesser, Mandy; Baumgartner, Daniel; Nast, Irina; Bansi, Jens; Kool, Jan; Bischof, Patrick; Bauer, Christoph,
2024.
Scientific Reports.
14(6598).
Available from: https://doi.org/10.1038/s41598-024-55692-4
-
Nast, Irina; Scheermesser, Mandy; Ernst, Markus; Sommer, Bettina; Schmid, Philipp Matthias; Weisenhorn, Martin; Bärtschi, Evelyne; Gomez, Daniela; Iten, Patricia; von Wartburg, Angela; Frey, Walter; Lünenburger, Lars; Bauer, Christoph,
2024.
Heliyon.
10(5), pp. e26931.
Available from: https://doi.org/10.1016/j.heliyon.2024.e26931
-
Sauerzopf, Lena; Spiess, Martina,
2024.
Auf Distanz reliable Assessments durchführen? : Erkenntnisse aus einem aktuellen Forschungsprojekt.
In:
7. Winterthurer Ergo-Gipfel, Winterthur, Schweiz, 2. März 2024.
-
Spescha, Nadia; Monhart, Muriel; Spiess, Martina,
2024.
In:
7. Winterthurer Ergo-Gipfel, Winterthur, Schweiz, 2. März 2024.
Available from: https://www.zhaw.ch/de/gesundheit/institute-zentren/ier/winterthurer-ergo-gipfel/7-winterthurer-ergo-gipfel/programm-7-winterthurer-ergo-gipfel/
Projects
Projects according to DDC 615: Pharmacology and therapeutics
-
MBSR and Stroke
-
Valedo Neck Therapy
Neck pain is a serious burden for the health system and the affected individuals. An analysis of the Global Burden of Disease Study 2013 lists it on the fourth rank - even before the "civilization disorders" migraine and diabetes. Because neck pain can have a wide variety of causes, individualized, personalized ...
-
Innovative models of collaboration for ambulant care
-
Bi-directional interactions of sensory perception, motor performance and fear of movement in the development of persistent low back pain
Low back pain (LBP) is one of the major health problems, with a lifetime prevalence of 85%. While the majority of acute LBP patients recover within a few weeks, a small minority becomes chronic (pain lasts > 3 months) and represents a huge burden in terms of pain, suffering, health care and social costs. Treatments ...
-
New antileishmanial and antitrypanosomal drugs
The aim is to develop a natural product derived LEAD compound with unrivalled potency against a parasitic disease into a clinical drug candidate, through preclinical development. This includes the establishment of a detailed structure-activity relationship (SAR), medicinal chemistry and organic synthesis, ADME-Tox ...